Table 3.
Multivariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival
| Hazard ratio (95% C.I.) | P-value | Hazard ratio (95% C.I.) | P-value | ||
|---|---|---|---|---|---|
| LINE-1 methylation levela | Q3, Q4 (n = 86) | ||||
| Q1, Q2 (n = 86) | 2.643 (1.443–4.482) | 0.002 | 2.248 (1.205–4.196) | 0.011 | |
| N staging | pN0 (n = 133) | ||||
| pN1 (n = 39) | 2.211 (1.176–4.157) | 0.014 | 2.749 (1.491–5.066) | 0.001 | |
| T staging | 0.025 | 0.130 | |||
| pT1 (n = 48) | Reference | Reference | |||
| pT2 (n = 52) | 1.943 (0.979–3.855) | 0.058 | 0.555 (0.211–1.458) | 0.232 | |
| pT3 (n = 47) | 0.941 (0.420–2.105) | 0.882 | 0.363 (0.121–1.091) | 0.071 | |
| pT4 (n = 25) | 0.433 (0.123–1.523) | 0.192 | 0.216 (0.053–0.889) | 0.034 | |
| Gross type | 0.076 | 0.064 | |||
| Mass forming (n = 141) | Reference | Reference | |||
| Periductal infiltrative (n = 8) | 0 | 0.964 | 0 | 0.972 | |
| Intraductal growth (n = 18) | 0.134 (0.018–0.971) | 0.047 | 0.123 (0.017–0.910) | 0.040 | |
| Mixed (n = 5) | 2.672 (0.827–8.638) | 0.101 | 2.878 (0.854–9.694) | 0.088 | |
| Lymphatic emboli | Absent (n = 102) | ||||
| Present (n = 70) | 2.519 (1.429–4.438) | 0.001 | 2.720 (1.168–6.337) | 0.020 | |
| Perineural invasion | Absent (n = 118) | ||||
| Present (n = 54) | 0.386 (0.181–0.822) | 0.014 | 0.373 (0.162–0.860) | 0.021 | |
| Differentiation | 0.083 | 0.638 | |||
| Well (n = 23) | Reference | ||||
| Moderate (n = 94) | 9.405 (1.283–68.943) | 0.027 | |||
| Poor (n = 55) | 9.671 (1.290–72.518) | 0.027 | |||
aRegardless of whether adjuvant and/or neoadjuvant therapy was included or not in the multivariate analysis, the hazard ratio of LINE-1 methylation level did not change